Vitamin D Deficiency Treatment Guidelines

Diagnostic Thresholds

The American College of Cardiology is not mentioned, however, treatment of vitamin D deficiency is recommended when serum 25-hydroxyvitamin D [25(OH)D] levels fall below 20 ng/mL, and strongly consider treatment for insufficiency (20-30 ng/mL) in patients with risk factors for bone disease, falls, or fractures 1, 2
Deficiency is defined as 25(OH)D < 20 ng/mL, requiring treatment, according to the Endocrine Society 1
Severe deficiency is defined as 25(OH)D < 10-12 ng/mL, significantly increasing the risk for osteomalacia and rickets, and demands urgent treatment, as per the Endocrine Society 1, 2
Insufficiency is defined as 25(OH)D 20-30 ng/mL, and treatment is recommended if the patient has osteoporosis, fracture risk, falls, or is elderly, as stated by the Endocrine Society 1

For deficiency (< 20 ng/mL), the loading phase involves ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) 50,000 IU once weekly for 8-12 weeks, as recommended by the Endocrine Society 1, 2
Cholecalciferol is preferred over ergocalciferol as it maintains serum levels longer and has superior bioavailability, according to the Endocrine Society 1
The maintenance phase involves transitioning to 1,500-2,000 IU daily after completing the loading dose, as stated by the Endocrine Society 1, 2
An alternative maintenance regimen is 50,000 IU monthly, equivalent to approximately 1,600 IU daily, as recommended by the National Kidney Foundation 3, 1

Elderly patients (≥ 65 years) should be treated with a minimum of 800 IU daily even without baseline measurement, as recommended by the Endocrine Society 1
Higher doses (700-1,000 IU daily) reduce fall and fracture risk in elderly patients, according to the Endocrine Society 1
Dark-skinned or veiled individuals with limited sun exposure should receive 800 IU daily without baseline testing, as stated by the Endocrine Society 1
Institutionalized individuals should receive 800 IU daily, as recommended by the Endocrine Society 1
Patients with chronic kidney disease (CKD) stages 3-5 should be treated with ergocalciferol or cholecalciferol, not active vitamin D analogs, as per the National Kidney Foundation 3
For CKD patients with GFR 20-60 mL/min/1.73m², standard nutritional vitamin D replacement is recommended, as stated by the National Kidney Foundation 3, 1

The minimum target level is 25(OH)D ≥ 30 ng/mL for optimal bone health and anti-fracture efficacy, as recommended by the Endocrine Society 1, 2
Anti-fall efficacy begins at ≥ 24 ng/mL, according to the Endocrine Society 1
The upper safety limit is 100 ng/mL, as stated by the Endocrine Society 1
25(OH)D levels should be rechecked after 3-6 months of treatment, as recommended by the Endocrine Society 1, 2

Adequate calcium intake (1,000-1,500 mg daily) from diet plus supplements is essential, as recommended by the Infectious Diseases Society of America 4, 1
Calcium supplements should be taken in divided doses (no more than 600 mg at once), as stated by the Endocrine Society 1
Weight-bearing exercise (30 minutes, 3 days per week) is recommended, as per the Infectious Diseases Society of America 4

Active vitamin D analogs (calcitriol, alfacalcidol, doxercalciferol, paricalcitol) should not be used to treat nutritional vitamin D deficiency, as they do not correct 25(OH)D levels, according to the National Kidney Foundation 3
Single very large doses (> 300,000 IU) should be avoided, as they may be inefficient or harmful, as stated by the Endocrine Society 1
Patients with normal vitamin D levels should not be supplemented, as benefits are only seen in those with documented deficiency, according to the Endocrine Society 1
Vitamin D deficiency should be corrected before initiating bisphosphonates to prevent hypocalcemia, as recommended by the Infectious Diseases Society of America 4

Daily doses up to 4,000 IU are generally safe for adults, as stated by the Endocrine Society 1
Toxicity is rare, typically occurring only with prolonged high doses (> 10,000 IU daily) and manifests as hypercalcemia, according to the Endocrine Society 1
Hypercalcemia should be monitored, especially in CKD patients, as recommended by the National Kidney Foundation 3